Table 1.
Case mix of patient with MTX-/Age-EBV-LPDs and DLBCLs in the head and neck.
| Case number |
Diagnosis | Age (y)/sex | Biopsy site | Collagen disease | Treatment of collagen disease | Histological type |
ISH and immunohistochemistry | |||
|---|---|---|---|---|---|---|---|---|---|---|
| EBER-ISH | LMP-1 | AID | Egr-1 | |||||||
| 1 | MTX-LPD | 32/F | LN (neck/axilla) | RA | MTX | NA | + (M) | + (W) | +++ (S) | +++ (S) |
| 2 | MTX-LPD | 57/M | LN (neck) | RA | MTX | LPL | +++ (M) | + (M) | +++ (S) | ++ (M) |
| 3 | MTX-LPD | 73/F | Oral mucosa (?) | RA | MTX/PSL | LPL | ++ (M) | + (M) | + (W) | NA |
| 4 | MTX-LPD | 52/M | LN (neck) | RA | MTX | HDMC | ++ (M) | ++ (W) | +++ (S) | +++ (S) |
| 5 | MTX-LPD | 57/F | LN (left neck and axilla) | RA | MTX/PSL | HDNS | +++ (M) | + (S) | +++ (S) | +++ (S) |
| 6 | MTX-LPD | 71/F | Septonasal mucosa | RA | MTX | NA | ++ (M) | + (M) | +++ (S) | +++ (S) |
| 7 | MTX-LPD | 60/F | LN (neck) | RA | MTX/PSL | LPL | ++ (M) | + (M) | +++ (S) | −/± (W) |
| 8 | MTX-LPD | 64/M | LN (neck) | RA | MTX/PSL | DLBCL | ++ (M) | + (M) | +++ (S) | +++ (S) |
| 9 | MTX-LPD | 44/M | Gingiva (right upper) | RA (Still's disease) |
MTX/PSL | DLBCL | ++ (M) | + (M) | +++ (S) | ++ (S) |
| 10 | MTX-LPD | 69/F | Gingiva (left upper) | RA | MTX | HD-like | ++ (M) | + (M) | +++ (S) | +++ (S) |
| 11 | MTX-LPD | 76/F | Gingiva (right upper) | RA | MTX | HD-like | ++ (M) | + (M) | +++ (S) | +++ (S) |
| 12 | MTX-LPD | 67/M | Hard palate (midline) | RA | MTX | NA | + (M) | −/±, (W) | −/± (W) | + (M) |
| 13 | MTX-LPD | 67/M | LN (neck) | RA | MTX/PSL | Follicular | ++ (M) | + (W) | ++ (S) | ++ (S) |
| 14 | MTX-LPD | 56/F | LN (left neck) | RA | MTX/PSL | MALT | + (M) | + (W) | +++ (S) | +++ (S) |
| 15 | MTX-LPD | 64/F | Skin (?) | RA | MTX/PSL | DLBCL | ++ (M) | ++ (S) | ++ (S) | +++ (S) |
| 16 | MTX-LPD | 59/M | Thyroid gland | RA | MTX/PSL | DLBCL | ++ (M) | ++ (W) | ++ (S) | +++ (S) |
| 17 | MTX-LPD | 74/F | Parotid gland (left) | RA | MTX/PSL | DLBCL | + (M) | ++ (S) | +++ (S) | ++ (S) |
| 18 | Age-LPD | 71/M | Mandibular bone (intraosseous) | N | NT | Polymorphous | ++ (S) | ++ (S) | +++ (S) | +++ (S) |
| 19 | Age-LPD | 76/M | Tongue/floor of mouth (right) | N | NT | Intermediate, DLBCL/CHL |
+ (W) | + (M) | +++ (S) | +++ (S) |
| 20 | DLBCL | 78/M | Maxillary sinus (right) | N | NT | DLBCL | −/± (W) | ++ (M) | −/± (W) | +++ (S) |
| 21 | DLBCL | 63/M | LN (left submandibular) | N | NT | DLBCL | + (W) | −/± (N) | −/± (W) | −/± (M) |
| 22 | DLBCL | 64/M | Gingiva (upper) | N | NT | DLBCL | + (W) | −/± (N) | −/± (W) | −/± (M) |
| 23 | DLBCL | 82/F | Gingiva (right lower) | N | NT | DLBCL | −/± (N) | ++ (W) | ++ (M) | ++ (S) |
| 24 | DLBCL | 69/F | Gingiva (left upper) | N | NT | DLBCL | + (M) | −/± (W) | −/± (W) | + (M) |
| 25 | DLBCL | 56/M | Gingiva (right upper) | N | NT | DLBCL | + (M) | −/± (W) | + (M) | + (S) |
| 26 | DLBCL | 52/F | Gingiva (upper) | N | NT | DLBCL | −/± (N) | −/± (N) | −/± (W) | + (W) |
| 27 | DLBCL | 46/M | Gingiva (left lower) | N | NT | DLBCL | −/± (W) | −/± (N) | −/± (N) | −/± (N) |
| 28 | DLBCL | 70/F | LN (left neck) | N | NT | DLBCL | −/± (W) | −/± (N) | −/± (W) | + (M) |
| 29 | DLBCL | 71/F | Maxillary sinus (left) | N | NT | DLBCL | −/± (N) | −/± (N) | −/± (W) | ++ (M) |
MTX: methotrexate; LPD: lymphoproliferative disorder; DLBCL: diffuse large B-cell lymphoma; RA: rheumatoid arthritis; LPL: lymphoplasmacytic lymphoma; HDMC: Hodgkin disease, mixed cellularity; HDNS: Hodgkin disease, nodular sclerosis; MALT: mucosa-associated lymphoid tissue; CHL: classical Hodgkin lymphoma; HD-like: Hodgkin disease-like; NA: not available; NT: no treatment; PSL: prednisolone; ?: unknown; LN: lymph node; LMP-1: Epstein-Barr virus- (EBV-) latent infection membrane protein-1; ISH: in situ hybridization; EBER: EBV-encoded small RNA; AID: activation-induced cytidine deaminase; Egr-1: early growth response transcription factor-1; diffuse: +++ (≧75%); focal: ++ (<75% to ≧25%); partial: + (<25% to ≧5%); few: −/± (negative/<5% or nonspecific); (S): strongly positive; (M): moderately positive; (W): weakly positive; (N): negative; M: male; F: female.